{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:03:51Z","timestamp":1781863431684,"version":"3.54.5"},"reference-count":18,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dulaglutide, a glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonist, has been approved for improving glycemic control and reducing the risk of cardiovascular (CV) adverse events. A previous result in healthy Chinese male subjects demonstrated the pharmacokinetic (PK) similarity of LY05008 and the licensed product dulaglutide, with comparable safety and immunogenicity profiles. A well\u2010controlled phase 3 study with an adequate sample size was subsequently conducted for safety and efficacy evaluation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a multicenter, randomized, open\u2010label, active comparator phase 3 study, Chinese adults diagnosed with type 2 diabetes mellitus (T2DM) were randomly assigned 1:1 to receive a subcutaneous injection of 1.5\u2009mg LY05008 or dulaglutide once weekly for 24\u2009weeks. The primary endpoint was the mean change in HbA1c from baseline to Week 24. The secondary endpoints included the mean change in HbA1c from baseline to Week 12; the proportion of patients who had achieved HbA1c\u2009\u2264\u20096.5% at Weeks 12 and 24; and the mean change in body weight, fasting plasma glucose (FPG) level, and 2\u2010h postprandial plasma glucose (PPG) level from baseline to Weeks 12 and 24. Safety, PK, and immunogenicity profiles were also included for data analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 440 patients were randomized to receive LY05008 (<jats:italic>n<\/jats:italic>\u2009=\u2009222) or dulaglutide (<jats:italic>n<\/jats:italic>\u2009=\u2009218). The mean changes in HbA1c from baseline to Week 24 in the LY05008 group and dulaglutide group were \u22121.44% and \u22121.41%, respectively, with a least square mean difference (LSMD) and 95% confidence interval (CI) of 0.06% (\u22120.08, 0.19) (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05). Efficacy equivalence could be demonstrated since the 95% CI between the reference drug and a biosimilar fell entirely within the range of (\u22120.4%, 0.4%). The mean changes in HbA1c from baseline to Week 12 in the LY05008 group and dulaglutide group were \u22121.47% and \u22121.39% (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05), respectively. At Week 12, 40.1% of patients who received LY05008 and 42.2% of those who received dulaglutide had a decrease in the HbA1c level to 6.5% or less, and 60.4% and 60.6% of patients in the LY05008 group and the dulaglutide group had a decrease in the HbA1C level &lt;\u20097%, respectively. At Week 24, 41.0% and 43.6% of patients achieved an HbA1c\u2009\u2264\u20096.5%. 55.9% and 66.5% of patients in the LY05008 group and the dulaglutide group achieved the HbA1c goal of &lt;\u20097%, respectively. The mean changes in body weight from baseline to Weeks 12 and 24 in the LY05008 group and dulaglutide group were \u22122.01 and \u22121.71\u2009kg (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) and \u22122.68 and \u22122.42\u2009kg (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05), respectively. The mean changes in FPG level from baseline to Weeks 12 and 24 in the LY05008 group and dulaglutide group were \u22122.578 and \u22122.681\u2009mmol\/L (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) and \u22122.222 and \u22122.690\u2009mmol\/L, respectively. In the LY05008 group and the dulaglutide group, the mean changes in 2\u2010h PPG levels from baseline to Weeks 12 and 24 were \u22124.364 and \u22124.800\u2009mmol\/L(<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05) and\u22123.502 and \u22124.217\u2009mmol\/L (<jats:italic>p<\/jats:italic>\u2009&gt;\u20090.05), respectively. The common treatment emergent adverse events (TEAEs) in the LY05008 and dulaglutide groups were decreased appetite, diarrhea, upper respiratory tract infection, hyperuricemia, nausea, urinary tract infection, and vomiting. Most TEAEs were mild to moderate in severity. No significant differences were observed between the groups in terms of TEAEs. Hypoglycemic events were noted in 0.9% of patients who had received LY05008 and in 3.7% of those who had received dulaglutide. Serious adverse events were reported in 4.1% of patients in the LY05008 group and in 3.7% of patients in the dulaglutide group. The PK parameter C<jats:sub>trough<\/jats:sub> and immunogenicity profiles were similar across the two treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The primary endpoint was met in this study through the demonstration of equivalent efficacy in HbA1c reduction in Chinese adults with T2DM between LY05008 and dulaglutide. Overall, the biosimilar product LY05008 showed comparable safety, PK, and immunogenicity profiles against the reference drug dulaglutide.<\/jats:p><jats:p><jats:bold>Trial Registration:<\/jats:bold> ClinicalTrials.gov identifier: CTR20221721<\/jats:p><\/jats:sec>","DOI":"10.1111\/1753-0407.70077","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T13:08:21Z","timestamp":1744376901000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Dulaglutide Biosimilar <scp>LY05008<\/scp> Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open\u2010Label, Active Comparator Study"],"prefix":"10.1111","volume":"17","author":[{"given":"Li","family":"Liu","sequence":"first","affiliation":[{"name":"Beijing Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"The Fourth Affiliated Hospital of Harbin Medical University  Harbin Heilongjiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwei","family":"Wang","sequence":"additional","affiliation":[{"name":"Zhumadian Central Hospital  Zhumadia Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jincheng Hospital  Jinchen Shanxi China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunbin","family":"Li","sequence":"additional","affiliation":[{"name":"Huzhou Central Hospital  Zhejiang China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Li","sequence":"additional","affiliation":[{"name":"Huizhou Central Hospital  Huizhou Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuguang","family":"Pang","sequence":"additional","affiliation":[{"name":"Jinan Central Hospital  Jinan City Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-6445","authenticated-orcid":false,"given":"Qifu","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Chongqing Medical University  Chongqing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Bian","sequence":"additional","affiliation":[{"name":"People's Hospital of Cangzhou  Cangzhou Hebei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Gu","sequence":"additional","affiliation":[{"name":"Second People's Hospital of Yibin  Yibin Sichuan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Shen","sequence":"additional","affiliation":[{"name":"Shunde Hospital of Southern Medical University  Foshan Guangdong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liujun","family":"Fu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Henan University of Science and Technology  Luoyang Henan China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiping","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong Boan Biotechnology Co. Ltd  Yantai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Shandong Boan Biotechnology Co. Ltd  Yantai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changlin","family":"Dou","sequence":"additional","affiliation":[{"name":"Shandong Boan Biotechnology Co. Ltd  Yantai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Zeng","sequence":"additional","affiliation":[{"name":"Yichang Central People's Hospital  Yichang Hubei China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-1798","authenticated-orcid":false,"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[{"name":"Beijing Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"e_1_2_1_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"e_1_2_1_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"e_1_2_1_10_4_1","first-page":"131","article-title":"Trulicity (Dulaglutide): A New GLP\u20101 Receptor Agonist Once\u2010Weekly Subcutaneous Injection Approved for the Treatment of Patients With Type 2 Diabetes","volume":"8","author":"Fala L.","year":"2015","journal-title":"American Health & Drug Benefits"},{"key":"e_1_2_1_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11\u2010s231"},{"key":"e_1_2_1_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21107"},{"key":"e_1_2_1_10_7_1","unstructured":"Eli Lilly \u201cTRULICITY (dulaglutide) U.S. Prescribing Information \u201daccessed April 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125469s046s052lbl.pdf."},{"key":"e_1_2_1_10_8_1","unstructured":"Eli Lilly \u201cTRULICITY (dulaglutide) CHN Prescribing Information \u201daccessed April 2024 https:\/\/db.yaozh.com\/jinkou?jinkouchanpinmingchengzhongwen%7Cjinkouchanpinmingchengyingwen=%E5%BA%A6%E6%8B%89%E7%B3%96%E8%82%BD%E6%B3%A8%E5%B0%84%E6%B6%B2&jinkoushangpinmingzhongwen%7Cjinkoushangpinmingyingwen=&jinkougongsimingchengzhongwen%7Cjinkougongsimingchengyingwen=&jinkouguigezhongwen=&jinkoujixingzhongwen=&jinkouzhucezhenghao=&jinkoufazhengriqistr=&jinkoufazhengriqiend."},{"key":"e_1_2_1_10_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389203717666160226144618"},{"issue":"13","key":"e_1_2_1_10_10_1","first-page":"851","article-title":"A Comprehensive Review of Biosimilars","volume":"8","author":"Shyamala K. Y.","year":"2019","journal-title":"World Journal of Pharmaceutical Research"},{"key":"e_1_2_1_10_11_1","unstructured":"US Food and Drug Administration \u201cScientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry \u201d2015 https:\/\/www.fda.gov\/media\/82647\/download."},{"key":"e_1_2_1_10_12_1","unstructured":"European Medicines Agency \u201cGuideline on Similar Biological Medicinal Products Containing Biotechnology\u2010Derived Proteins as Active Substance: Non\u2010Clinical and Clinical Issues \u201d2014 https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010similar\u2010biological\u2010medicinal\u2010products\u2010containing\u2010biotechnology\u2010derived\u2010proteins\u2010active_en\u20100.pdf."},{"key":"e_1_2_1_10_13_1","unstructured":"China National Medical Products Administration \u201cTechnical Guidelines for Research and Evaluation of Biosimilars \u201d2015 https:\/\/www.cde.org.cn\/zdyz\/domesticinfopage?zdyzIdCODE=f044cdf4b7d7286aa12ffb85fc81a74c."},{"key":"e_1_2_1_10_14_1","unstructured":"World Health Organization \u201cGuidelines on Evaluation of Biosimilars \u201d2022 https:\/\/www.who.int\/publications\/m\/item\/guidelines\u2010on\u2010evaluation\u2010of\u2010biosimilars."},{"key":"e_1_2_1_10_15_1","unstructured":"National Medicine Product Administration \u201cDesigning of Clinical Trials for Developing of Biosimilar Product of Liraglutide Injection Guidance for Industry \u201d2020 https:\/\/www.ccfdie.org\/zryyxxw\/cfdazsjg\/ypspzx\/webinfo\/2020\/06\/1592158766215945.htm."},{"key":"e_1_2_1_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01462-w"},{"key":"e_1_2_1_10_17_1","unstructured":"US Food and Drug Administration \u201cDiabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products Guidance for Industry \u201d2023 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/diabetes\u2010mellitus\u2010efficacy\u2010endpoints\u2010clinical\u2010trials\u2010investigating\u2010antidiabetic\u2010drugs\u2010and\u2010biological."},{"key":"e_1_2_1_10_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2810"},{"key":"e_1_2_1_10_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2189009"}],"container-title":["Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1753-0407.70077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T05:49:38Z","timestamp":1745905778000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1753-0407.70077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1111\/1753-0407.70077"],"URL":"https:\/\/doi.org\/10.1111\/1753-0407.70077","archive":["Portico"],"relation":{},"ISSN":["1753-0393","1753-0407"],"issn-type":[{"value":"1753-0393","type":"print"},{"value":"1753-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70077"}}